^DJI - Dow Jones Industrial Average
| Previous Close | 26,062.12 |
| Open | 26,076.21 |
| Volume | 186,108,603 |
| Day's Range | 26,076.21 - 26,317.34 |
| 52 Week Range | 22,219.11 - 26,616.71 |
| Avg. Volume | 269,322,968 |
Yahoo Finance•5 hours agoTrump threatens 10% tariffs on another $200 billion of Chinese goods as trade war heats up
Midday Movers September 18th, 2018
- MarketWatch•55 minutes ago
Health care ETF surges toward record in a broad sector rally
The SPDR Health Care Select Sector ETF rose 0.7% toward a record high in afternoon trade Tuesday, with 55 of its 63 equity components gaining ground. Among the ETF's (XLV) members which are also Dow Jones Industrial Average components, Pfizer Inc.'s stock shot up 1.5%, putting it on track to close at the highest level since December 2001. Also, shares of Johnson & Johnson gained 0.6% toward an eight-month high, Merck & Co. Inc. tacked on 0.4% to sit just shy of its 17-year high reached last Thursday, and UnitedHealth Group Inc. slipped 0.1% and was 2.2% below its Sept. 6 record close of $269.65. The XLV's biggest gainer was Abiomed Inc.'s stock , which rallied 2.7%, while its biggest decliner was AbbVie Inc.'s stock , which shed 2.1% after California sued the company alleging the payment of illegal kickbacks. The XLV has rallied 11% over the past three months, while the Dow has tacked on 5.2%.
- MarketWatch•1 hour ago
AbbVie stock drops 2% after California lawsuit alleges illegal activity used to push blockbuster drug
AbbVie Inc. shares dropped 2.3% in extremely heavy Tuesday afternoon trade after California's insurance commissioner filed a lawsuit alleging that the company paid illegal kickbacks to push prescribing of its blockbuster arthritis drug Humira. According to the lawsuit, AbbVie also used registered nurse "ambassadors" to work with patients on behalf of doctors, as long as doctors prescribed Humira, while nurses downplayed the drug's side effects and risks. The California Department of Insurance has asked for compensation of three times the amount of each claim that was made for Humira, along with civil penalties for each fraudulent claim, attorney's fees and other relief; the state cited data that private insurers paid more than $1.29 billion on Humira in recent years and had more than 274,000 claims. The case was brought forward by a whistleblower who served as an AbbVie "nurse educator" and "patient ambassador" between 2013 and 2014, Lazaro Suarez, who became troubled about the program's "emphasis on the bottom line" and attended training where ambassadors were told to hide serious cancer and infection risks from patients. California filed to intervene in the case on August 31 through its state insurance commissioner, Dave Jones, according to the lawsuit. AbbVie shares have dropped 5.3% over the last three months, compared with a 4.9% rise in the S&P 500 and a 5.3% rise in the Dow Jones Industrial Average .
Reuters•1 hour agoWall Street rebounds in the face of heated trade row
By Stephen Culp NEW YORK (Reuters) - Wall Street bounced back on Tuesday, led by gains in consumer discretionary, technology and industrial stocks as investors shrugged off escalating trade rhetoric between ...
- MarketWatch•1 hour ago
Stocks vault higher as investors look past intensifying U.S.-China trade fight
U.S. stocks vault higher Tuesday afternoon, with investors shrugging off escalating trade tensions to instead focus on an economy that remains strong by many measures
Market Realist•1 hour agoInventory Data: A Boost for Oil?
In the week that ended on September 7, US crude oil inventories fell 3% below their five-year average. In the previous week, inventories were on par with their five-year average.
- MarketWatch•1 hour ago
Dow jumps 250 points, moves to within 1.2% of its record as the stock market hits session high
The Dow Jones Industrial Average late-afternoon Tuesday jumped by more than 240 points, trading at session highs as Wall Street investors shrugged off escalating trade tensions to focus on a healthy domestic economy. The Dow was up 246 points, or 0.9%, at 26,309, putting the blue-chip gauge about 1.2% shy of its Jan. 26 record at 26,616.71. The rally comes despite China's decision to impose tariffs of 5% to 10% on $60 billion worth of U.S. products that will take effect Sept. 24. That news is in direct response to the Trump administration's announcement of 10% tariffs on $200 billion in Chinese goods, which will be implemented on the same date. The clashes between Beijing and Washington have been a source of anxiety for the market, but it hasn't prevented equities from mostly trending higher on the back of strong jobs and healthy corporate earnings. Meanwhile, the S&P 500 index climbed 0.7% at 2,910, while the Nasdaq Composite Index advanced 1% at 7,976.
Market Realist•2 hours agoWill US Markets Shrug Off Trade Worries Again?
US markets have been quite resilient for the most part in 2018—even in the face of escalating trade tensions between the United States and the European Union, Canada, Mexico, and China. The markets have tended to dive initially only to erase most of the losses later on—probably because the markets believe that the United States has the upper hand in the trade situation and has less to lose. In contrast, China’s major indexes have plunged ~25.0% from their highs this year, and its economic growth is also feeling the pressure from these escalating trade tensions.
Associated Press•2 hours agoUS stocks rise as traders size up new US tariffs on China
Technology and consumer-focused companies led U.S. stocks broadly higher Tuesday afternoon, reversing much of the market's losses from a day earlier. Health care stocks also posted solid gains.
Yahoo Finance Video•2 hours agoLittle movement in markets as China and U.S. escalate trade war
Markets subdued as China and America ratchet up tariffs on goods. Yahoo Finance's Seana Smith, Dion Rabouin, Kathy Jones, Sr. VP and Chief Fixed Income Strategist and Liz Young of BNY Mellon Snr. Investment Strategist, discuss.
